Cosmos Health

Q2 FY2026 EarningsQ3 FY26 preliminary revenue of ~$17.4M exceeded consensus of $17.28M by 0.71%, marking the company's highest third-quarter revenue on record. Nine-month revenue reached $54.3M, up 19% YoY, driven by growth across contract manufacturing (Cana Laboratories) and pharmaceutical distribution (CosmoFarm). Management reaffirmed its FY26 revenue guidance of over $90M, significantly above current expectations, signaling a robust outlook for the upcoming Q4.